Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks where Wall Street’s positive outlook is supported by strong fundamentals.
Sprouts (SFM)
Consensus Price Target: $183.43 (24.8% implied return)
Playing on the secular trend of healthier living, Sprouts Farmers Market (NASDAQ:SFM) is a grocery store chain emphasizing natural and organic products.
Why Do We Watch SFM?
- Aggressive strategy of rolling out new stores to gobble up whitespace is prudent given its same-store sales growth
- Comparable store sales rose by 7.5% on average over the past two years, demonstrating its ability to drive increased spending at existing locations
- Projected revenue growth of 11.7% for the next 12 months is above its six-year trend, pointing to accelerating demand
Sprouts’s stock price of $147 implies a valuation ratio of 27.3x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
BioMarin Pharmaceutical (BMRN)
Consensus Price Target: $97.62 (71.3% implied return)
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Are We Fans of BMRN?
- Market share has increased this cycle as its 17.1% annual revenue growth over the last two years was exceptional
- Incremental sales significantly boosted profitability as its annual earnings per share growth of 22.2% over the last five years outstripped its revenue performance
- Free cash flow margin jumped by 13.6 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
BioMarin Pharmaceutical is trading at $57 per share, or 13x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
IonQ (IONQ)
Consensus Price Target: $49.57 (35.3% implied return)
Founded by quantum physics pioneers from the University of Maryland and Duke University in 2015, IonQ (NYSE:IONQ) develops quantum computers that process information using trapped ions to solve complex computational problems beyond the capabilities of traditional computers.
Why Are We Backing IONQ?
- Market share has increased this cycle as its 78.9% annual revenue growth over the last two years was exceptional
- Adjusted operating margin expanded by 5,803.2 percentage points over the last five years as it scaled and became more efficient
- Cash burn has decreased over the last five years, showing the company is becoming a more self-sustaining business
At $36.65 per share, IonQ trades at 68.9x forward price-to-sales. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.
Stocks We Like Even More
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.